MRNA Stock Forecast 2025-2026
Distance to MRNA Price Targets
MRNA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Moderna (MRNA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MRNA and similar high-potential opportunities.
Latest MRNA Stock Price Targets & Analyst Predictions
Based on our analysis of 28 Wall Street analysts, MRNA has a neutral consensus with a median price target of $40.00 (ranging from $25.00 to $212.00). The overall analyst rating is Buy (6.4/10). Currently trading at $32.12, the median forecast implies a 24.5% upside. This outlook is supported by 6 Buy, 17 Hold, and 4 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRNA Analyst Ratings
MRNA Price Target Range
Latest MRNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | JP Morgan | Jessica Fye | Underweight | Maintains | $33.00 |
| Mar 13, 2025 | Citigroup | Geoff Meacham | Neutral | Initiates | $40.00 |
| Feb 19, 2025 | UBS | Eliana Merle | Buy | Maintains | $78.00 |
| Feb 18, 2025 | Barclays | Gena Wang | Equal-Weight | Downgrade | $45.00 |
| Feb 18, 2025 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $40.00 |
| Feb 11, 2025 | B of A Securities | Tim Anderson | Underperform | Maintains | $34.00 |
| Jan 29, 2025 | Goldman Sachs | Salveen Richter | Neutral | Downgrade | $51.00 |
| Jan 28, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $99.00 |
| Jan 27, 2025 | Evercore ISI Group | Cory Kasimov | In-Line | Maintains | $50.00 |
| Jan 15, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $38.00 |
| Jan 8, 2025 | UBS | Eliana Merle | Buy | Maintains | $96.00 |
| Dec 18, 2024 | Argus Research | John Eade | Hold | Downgrade | $0.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Underperform | Reinstates | $41.00 |
| Nov 26, 2024 | JP Morgan | Jessica Fye | Underweight | Maintains | $45.00 |
| Nov 18, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $69.00 |
| Nov 18, 2024 | HSBC | Yifeng Liu | Buy | Upgrade | $58.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Underperform | Initiates | $40.00 |
| Nov 8, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Nov 8, 2024 | Barclays | Gena Wang | Overweight | Maintains | $111.00 |
| Nov 4, 2024 | JP Morgan | Jessica Fye | Underweight | Maintains | $59.00 |
Moderna Inc. (MRNA) Competitors
The following stocks are similar to Moderna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Moderna Inc. (MRNA) Financial Data
Moderna Inc. has a market capitalization of $12.17B with a P/E ratio of 25.0x. The company generates $3.24B in trailing twelve-month revenue with a -110.0% profit margin.
Revenue growth is -65.6% quarter-over-quarter, while maintaining an operating margin of -129.0% and return on equity of -28.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Moderna Inc. (MRNA) Business Model
About Moderna Inc.
Develops transformative mRNA-based medicines and vaccines.
Moderna generates revenue primarily through the research, development, and commercialization of vaccines and therapeutics based on its proprietary mRNA technology. The company has gained significant recognition and financial success from its COVID-19 vaccine, which has driven substantial sales and partnerships with governments and health organizations.
Moderna's research pipeline is diverse, addressing not only infectious diseases but also areas like oncology, cardiovascular diseases, and rare genetic disorders. The company is headquartered in Cambridge, Massachusetts, and is a leader in the biotechnology sector, known for its rapid advancement in drug development and commitment to tackling global health challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5,800
CEO
Mr. Stephane Bancel
Country
United States
IPO Year
2018
Website
www.modernatx.comModerna Inc. (MRNA) Latest News & Analysis
Moderna (MRNA) saw record sales from its COVID-19 vaccine in 2022, but projections for ongoing demand have not met expectations, resulting in a significant business decline.
Moderna's declining demand for COVID-19 vaccines signals potential revenue instability, impacting future profitability and investor confidence in the biotech sector.
Moderna shares fell after reports indicated Robert F. Kennedy Jr. may withdraw funding for its bird flu vaccine project.
Moderna's stock decline reflects potential funding uncertainty for its bird flu vaccine, which could impact future revenue and growth prospects.
Moderna (MRNA) is currently highly monitored by Zacks.com users, indicating increased investor interest and potential market developments to watch for the stock.
Increased attention on Moderna from Zacks.com users may indicate heightened interest or potential volatility, impacting trading strategies and stock performance.
Valuation is crucial in investing, with opportunities to find stocks that are considered great bargains.
Valuation impacts investment decisions; identifying undervalued stocks can lead to significant returns, enhancing portfolio performance and risk management.
The mRNA Vaccines Market grew from $9.32B in 2024 to $10.40B in 2025, with a projected CAGR of 11.86%, reaching $18.28B by 2030, driven by innovations in technology and production methods.
The mRNA vaccines market's rapid growth and innovation signal strong investment opportunities. Advances in technology and regulatory support are reshaping healthcare, attracting capital and driving competition.
Moderna (MRNA) closed at $34.71 in the latest trading session, reflecting a gain of 0.26% from the previous day.
Moderna's slight price increase indicates stability in its stock, potentially reflecting investor confidence or positive market sentiment, impacting future trading decisions.
Frequently Asked Questions About MRNA Stock
What is Moderna Inc.'s (MRNA) stock forecast for 2025?
Based on our analysis of 28 Wall Street analysts, Moderna Inc. (MRNA) has a median price target of $40.00. The highest price target is $212.00 and the lowest is $25.00.
Is MRNA stock a good investment in 2025?
According to current analyst ratings, MRNA has 6 Buy ratings, 17 Hold ratings, and 4 Sell ratings. The stock is currently trading at $32.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRNA stock?
Wall Street analysts predict MRNA stock could reach $40.00 in the next 12 months. This represents a 24.5% increase from the current price of $32.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Moderna Inc.'s business model?
Moderna generates revenue primarily through the research, development, and commercialization of vaccines and therapeutics based on its proprietary mRNA technology. The company has gained significant recognition and financial success from its COVID-19 vaccine, which has driven substantial sales and partnerships with governments and health organizations.
What is the highest forecasted price for MRNA Moderna Inc.?
The highest price target for MRNA is $212.00 from at , which represents a 560.0% increase from the current price of $32.12.
What is the lowest forecasted price for MRNA Moderna Inc.?
The lowest price target for MRNA is $25.00 from at , which represents a -22.2% decrease from the current price of $32.12.
What is the overall MRNA consensus from analysts for Moderna Inc.?
The overall analyst consensus for MRNA is neutral. Out of 28 Wall Street analysts, 6 rate it as Buy, 17 as Hold, and 4 as Sell, with a median price target of $40.00.
How accurate are MRNA stock price projections?
Stock price projections, including those for Moderna Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
